Select acquires remainder of subsidiaries

By Melissa Trudinger
Tuesday, 30 November, 2004

Select Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.

The institute will be issued 4 million new shares plus 2 million options in Select Vaccines in return for its equity.

Ongoing R&D programs being conducted by the Burnet Institute for the two companies will continue to be funded through December 2005.

Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...

The breakthrough should help advance our understanding into how human heart valves develop,...

3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...

Content from other channels on our network

UNSW engineers awarded grant for critical renewables research

Australia–Japan laser a new step towards advanced defence manufacturing

Robots have a positive effect on employment and productivity: report

Hazer technology to be evaluated by major Japanese power utility

Researchers recover silver from end‍-‍of‍-‍life solar panels

A new national approach to clinical governance

Opinion: The debate over the government's aged care algorithm is missing the point

Commonwealth Home Support Program extended to 30 June 2029

When Connectivity Becomes Critical Care — Webinar

Unregistered doctor convicted after patient is hospitalised following medical procedure

Zip Water releases 2025 Sustainability Report

Australia's EV fleet transition will be won or lost at the depot

Smart stormwater system removes harmful pollutants

Researchers create compact supercapacitor designed for reuse

ARRC Gold Coast calls for market certainty on plastics